Retatrutide Weight Loss by Starting BMI
Your starting BMI influences both the absolute pounds you lose and the health impact of that weight loss. Here is what Phase 2 data tells us about retatrutide outcomes across different BMI categories.
Patients come to retatrutide from different starting points -- BMI 28 with prediabetes, BMI 38 with type 2 diabetes, BMI 48 with multiple comorbidities. Phase 2 data (Jastreboff et al., NEJM 2023) showed that retatrutide produced significant weight loss across the BMI spectrum, but the absolute pounds lost and the clinical impact of that loss vary by where you start. Understanding these differences helps set realistic, personalized expectations.
Data Limitations
BMI-stratified results from Phase 2 are limited by small subgroup sizes. Phase 3 will provide more detailed analysis by starting BMI. Retatrutide is investigational.
Percentage vs Absolute Weight Loss
A crucial distinction: percentage weight loss tends to be relatively consistent across BMI categories (20-24% at the highest dose), but absolute weight loss in pounds varies dramatically. A 200-pound patient losing 24% loses 48 pounds. A 350-pound patient losing 24% loses 84 pounds. The percentage is the same; the practical impact differs.
Outcomes by BMI Category
For patients with BMI 27-30 (overweight): expected loss of approximately 15-20% body weight (30-45 pounds). This group may achieve normal BMI range. Health improvements include resolution of prediabetes, blood pressure normalization, and reduced joint stress. For patients with BMI 30-35 (class I obesity): expected loss of approximately 20-24% body weight (45-65 pounds). Many achieve overweight or normal BMI range. Diabetes risk drops dramatically. For patients with BMI 35-40 (class II obesity): expected loss of approximately 20-24% body weight (55-80 pounds). Most move to class I obesity or overweight category. Major improvements in mobility, sleep, and metabolic health. For patients with BMI 40+ (class III obesity): expected loss of approximately 20-24% body weight (70-100+ pounds). Significant BMI reduction but may remain in obesity category. Dramatic improvements in quality of life and comorbidity burden despite remaining elevated BMI.
The Health Impact Varies by Starting BMI
Interestingly, patients with lower starting BMIs may see the most dramatic health improvements relative to weight lost. Moving from BMI 33 to 25 crosses the threshold from obesity to normal weight, resolving many weight-related conditions entirely. Moving from BMI 48 to 37 provides enormous health benefit but still leaves the patient in the obesity category with ongoing health risks. This does not diminish the value of treatment for higher BMI patients -- the absolute health improvement from losing 80+ pounds is massive -- but it helps set appropriate expectations for what the final result looks like.
To start your weight loss journey, visit our treatments page.
Medical Disclaimer
This article is for educational purposes only. Retatrutide is not FDA-approved. Results from Phase 2 data (Jastreboff et al., NEJM 2023). Individual results vary. Consult a healthcare provider.
Start From Any BMI
Effective treatment at every starting point. Semaglutide from $99/mo.
Get Started TodayMore on Retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).